{"id":259,"date":"2026-10-26T14:38:12","date_gmt":"2026-10-26T14:38:12","guid":{"rendered":"https:\/\/s2.designcostaging.com\/clients\/monopar\/?page_id=259"},"modified":"2026-11-01T18:12:19","modified_gmt":"2026-11-01T18:12:19","slug":"about","status":"publish","type":"page","link":"https:\/\/s2.designcostaging.com\/clients\/monopar\/about\/","title":{"rendered":"About"},"content":{"rendered":"
\n
\n
\n

Experience, Expertise and Dedication to Advance New Therapies for Patients <\/h3><\/div><\/div>\n<\/div>\n\n
\n

Monopar Therapeutics is a clinical-stage biotechnology company developing next generation targeted therapies for Wilson disease, a rare genetic disorder, and for cancer. We are focused on developing novel therapies in areas of significant unmet patient need to improve lives. We have a passion for helping bring treatments to patients who often have limited options. <\/p>\n<\/div><\/div>\n\n

Learn More<\/a><\/div>\n<\/div>\n<\/div>\n<\/div>\n\n
\n
\n
\n
<\/span><\/div>\n<\/div>\n\n
\n
\n
<\/div><\/div>\n\n

Our management team has extensive experience in building companies and developing therapeutics through regulatory approval and commercialization.<\/p>\n<\/div><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n

\n
\n
\n

Leadership<\/h2><\/div><\/div>\n<\/div>\n<\/div>\n\n
\n
\n
<\/span><\/a><\/div>

Christopher Starr, PhD <\/a><\/h3>

Co-Founder and Executive Chairman of the Board<\/p>\n<\/div><\/div><\/div><\/div>\n<\/div>\n\n

\n
<\/span><\/div>

Chandler Robinson, MD, MBA, MSc <\/h3>

Co-Founder, CEO<\/p>\n<\/div><\/div><\/div><\/div>\n<\/div>\n\n

\n
<\/span><\/div>

Andrew Cittadine, MBA <\/h3>

Chief Operating Officer<\/p>\n<\/div><\/div><\/div><\/div>\n<\/div>\n\n

\n
<\/span><\/div>

Susan Rodriguez<\/h3>

Chief Commercial and Strategy Officer<\/p>\n<\/div><\/div><\/div><\/div>\n<\/div>\n\n

\n
<\/span><\/div>

Jeffrey Kent, MD, FACG, FACP<\/h3>

EVP, Medical Affairs<\/p>\n<\/div><\/div><\/div><\/div>\n<\/div>\n\n

\n
<\/span><\/div>

Quan Vu <\/h3>

Chief Financial Officer<\/p>\n<\/div><\/div><\/div><\/div>\n<\/div>\n<\/div>\n<\/div>\n\n

\n
\n
\n

Board of Directors<\/h2><\/div><\/div>\n<\/div>\n<\/div>\n\n
\n
\n
<\/span><\/a><\/div>

Christopher Starr, PhD <\/a><\/h3>

Co-Founder and Executive Chairman of the Board<\/p>\n<\/div><\/div><\/div><\/div>\n<\/div>\n\n

\n
<\/span><\/div>

Raymond W. Anderson, MBA, MS<\/h3>

Board Member<\/p>\n<\/div><\/div><\/div><\/div>\n<\/div>\n\n

\n
<\/span><\/div>

Kim R. Tsuchimoto<\/h3>

Board Member<\/p>\n<\/div><\/div><\/div><\/div>\n<\/div>\n\n

\n
<\/span><\/div>

Lavina Talukdar, CFA<\/h3>

Board Member<\/p>\n<\/div><\/div><\/div><\/div>\n<\/div>\n\n

\n
<\/span><\/div>

Nicole Sweeny<\/h3>

Board Member<\/p>\n<\/div><\/div><\/div><\/div>\n<\/div>\n\n

<\/div>\n<\/div>\n<\/div>\n\n
\n
\n
\n
<\/span><\/div>\n<\/div>\n\n
\n

Christopher Starr, PhD<\/h2><\/div><\/div>\n\n

Co-Founder and Executive Chairman of the Board<\/h4><\/div><\/div>\n\n

Dr. Starr has helped bring 6 orphan product drugs to market, and as co-founder and CEO of Raptor Pharmaceuticals (recently purchased by Horizon Pharma), oversaw the approval, launch, and successful commercialization of Procysbi\u00ae. He served as Raptor\u2019s initial CEO since its inception in 2006 through 2014 and continued to serve on Raptor\u2019s board of directors until Raptor was sold to Horizon Pharma in October 2016. Dr. Starr co-founded BioMarin Pharmaceutical Inc. in 1997 where he last served as Senior Vice President and Chief Scientific Officer until starting Raptor in 2006. As Senior Vice President at BioMarin, Dr. Starr was responsible for managing a Scientific Operations team of 181 research, process development, manufacturing and quality personnel through the successful development of commercial manufacturing processes for its enzyme replacement and small molecule products, and supervised the cGMP design, construction and licensing of BioMarin's proprietary biological manufacturing facility. From 1991 to 1998, Dr. Starr supervised research and commercial programs at BioMarin's predecessor company, Glyko, Inc., where he served as Vice President of Research and Development. Prior to his tenure at Glyko, Inc., Dr. Starr was a National Research Council Associate at the National Institutes of Health. Dr. Starr earned a B.S. from Syracuse University and a Ph.D. in Biochemistry and Molecular Biology from the State University of New York Health Science Center, in Syracuse, New York.<\/p>\n<\/div><\/div>\n<\/div>\n<\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-259","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/s2.designcostaging.com\/clients\/monopar\/wp-json\/wp\/v2\/pages\/259","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/s2.designcostaging.com\/clients\/monopar\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/s2.designcostaging.com\/clients\/monopar\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/s2.designcostaging.com\/clients\/monopar\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/s2.designcostaging.com\/clients\/monopar\/wp-json\/wp\/v2\/comments?post=259"}],"version-history":[{"count":109,"href":"https:\/\/s2.designcostaging.com\/clients\/monopar\/wp-json\/wp\/v2\/pages\/259\/revisions"}],"predecessor-version":[{"id":3025,"href":"https:\/\/s2.designcostaging.com\/clients\/monopar\/wp-json\/wp\/v2\/pages\/259\/revisions\/3025"}],"wp:attachment":[{"href":"https:\/\/s2.designcostaging.com\/clients\/monopar\/wp-json\/wp\/v2\/media?parent=259"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}